Pulmatrix and Cullgen continue to pursue their merger while granting each other waivers to explore alternatives.
The total cash and cash equivalents balance of Pulmatrix as of September 30, 2025, was $4.8 million, with anticipated operational funding into at least the fourth quarter of 2026.
Pulmatrix's iSPERSE™ technology and clinical assets, including assets like PUR3100 and PUR1800, are highlighted in the filing.
Merger Progress
Form S-4 filing declared effective in May 2025 with stockholders' approval in June 2025; pending approval from CSRC for the merger.
Financial Position
Cash and cash equivalents balance of $4.8 million as of September 30, 2025, expected to fund operations into Q4 2026.
Clinical Assets
Assets like PUR3100, an orally inhaled DHE for acute migraine, and PUR1800, a Narrow Spectrum Kinase Inhibitor for AECOPD, are key focuses.
- Pulmatrix and Cullgen's mutual agreement to waive the 'No Solicitation' clause shows openness and flexibility in exploring alternate transactions.
- The merger progress is subject to closing conditions, including approval from the China Security Regulatory Commission.
- Pulmatrix's innovative iSPERSE™ technology enhances drug delivery for certain diseases, providing a competitive edge in the market.
With ongoing merger negotiations and a solid financial position, Pulmatrix is well-positioned for growth and continued development of its clinical assets using the innovative iSPERSE™ technology.